• Dheeraj Goswami, Matthew DiGiusto, Rajeev Wadia, Sean Barnes, Jamie Schwartz, Diana Steppan, Kristen Nelson-McMillan, Richard Ringel, and Jochen Steppan.
• Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD.
• J. Cardiothorac. Vasc. Anesth. 2020 Aug 1; 34 (8): 2215-2223.

AbstractAnticoagulation is an essential component for patients undergoing cardiopulmonary bypass or extracorporeal membrane oxygenation and for those with ventricular assist devices. However, thrombosis and bleeding are common complications. Heparin continues to be the agent of choice for most patients, likely owing to practitioners' comfort and experience and the ease with which the drug's effects can be reversed. However, especially in pediatric cardiac surgery, there is increasing interest in using bivalirudin as the primary anticoagulant. This drug circumvents certain problems with heparin administration, such as heparin resistance and heparin-induced thrombocytopenia, but it comes with additional challenges. In this manuscript, the authors review the literature on the emerging role of bivalirudin in pediatric cardiac surgery, including its use with cardiopulmonary bypass surgery, extracorporeal membrane oxygenation, ventricular assist devices, and interventional cardiology. Moreover, they provide an overview of bivalirudin's pharmacodynamics and monitoring methods.Copyright © 2020 Elsevier Inc. All rights reserved.

17 keywords...

hide…